NO992336L - Raf-kinase-inhibitorer - Google Patents

Raf-kinase-inhibitorer

Info

Publication number
NO992336L
NO992336L NO992336A NO992336A NO992336L NO 992336 L NO992336 L NO 992336L NO 992336 A NO992336 A NO 992336A NO 992336 A NO992336 A NO 992336A NO 992336 L NO992336 L NO 992336L
Authority
NO
Norway
Prior art keywords
methylphenyl
cyclohexylpropionylamino
acetoxybenzamide
hydroxybenzamide
raf kinase
Prior art date
Application number
NO992336A
Other languages
English (en)
Other versions
NO992336D0 (no
Inventor
Phillip John Hedge
Francis Thomas Boyle
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of NO992336D0 publication Critical patent/NO992336D0/no
Publication of NO992336L publication Critical patent/NO992336L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfinnelse vedrører farmasøytiske blandinger omfattende inhibitorer av raf-kinase med formel (l), hvori: R1 og R2 er substituenter på fenylringene; p, som kan ha de samme eller forskjellige verdier for R1 og R2, skal være 0-3, og når p er 2 eller 3, kan gruppene være de samme eller forskjellige; R3 er CMalkyl; q er 0-4; R4 er aryl eller cykloalkyl, hvori R4 eventuelt er substituert med opp til 3 subsituenter eller et farmasøytisk akseptabelt salt eller en in vivo hydrolyserbar ester derav og en farmasøytisk akseptabel bærer, under den forutsetning at N-[5-(3-cykloheksyl-propionylamino)-2-metylfenyl]-4-hydroksybenzamid, N-[5-(3-cyklopentylpropionylamino)-2-metylfenyl]-4-acetoksybenzamid, N-[5-(3-fenylpropionylamino)-2-metylfeny!]-4-acetoksybenzamid, N-[5-(4-cykloheksylbutyrylamino)-2-metylfenyl]-4-acetoksybenzamid, N-[5-(2-cykloheksylacetylamino)-2-metylfenyl]-acetoksybenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-aminobenzamid, Nt[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-nitrobenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-hydroksymetylbenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-metoksykarbonyl-benzamid, N-[5-(3-cykloheksylpropionylamino)2-metylfenyl]-2-hydroksybenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-3-hydroksybenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-benzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-acetoksybenzarnidog N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-hydroksybenzamider utelukket. Fremgangsmåter for deres fremstilling og deres anvendelse som terapeutiske midler. EEn spesiell anvendelse er i kreftterapi.
NO992336A 1996-11-16 1999-05-14 Raf-kinase-inhibitorer NO992336L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9623833.2A GB9623833D0 (en) 1996-11-16 1996-11-16 Chemical compound
PCT/GB1997/003102 WO1998022103A1 (en) 1996-11-16 1997-11-12 Raf kinase inhibitors

Publications (2)

Publication Number Publication Date
NO992336D0 NO992336D0 (no) 1999-05-14
NO992336L true NO992336L (no) 1999-05-14

Family

ID=10803023

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992336A NO992336L (no) 1996-11-16 1999-05-14 Raf-kinase-inhibitorer

Country Status (8)

Country Link
EP (1) EP0941084A1 (no)
JP (1) JP2001504478A (no)
AU (1) AU4956297A (no)
CA (1) CA2267782A1 (no)
GB (1) GB9623833D0 (no)
NO (1) NO992336L (no)
WO (1) WO1998022103A1 (no)
ZA (1) ZA9710314B (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
IL134723A0 (en) 1997-09-23 2001-04-30 Zeneca Ltd Amide derivatives for the treatment of diseases mediated by cytokines
UA67763C2 (uk) * 1997-12-22 2004-07-15 Байер Фармасьютікалс Корпорейшн Арил- та гетероарилзаміщені гетероциклічні похідні сечовини, фармацевтична композиція та спосіб лікування захворювання, спричиненого кіназою raf
TR200002618T2 (tr) * 1997-12-22 2001-04-20 Bayer Corporation Sübstitüe edilmiş heterosiklik üreler kullanılarak raf kinazın inhibe edilmesi
BR9910467A (pt) * 1998-05-15 2001-01-09 Astrazeneca Ab Composto derivado de amida, processo para a preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida
AU749293B2 (en) * 1998-05-15 2002-06-20 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
TR200100300T2 (tr) 1998-08-04 2001-07-23 Astrazeneca Ab Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri
PL346854A1 (en) 1998-09-25 2002-03-11 Astrazeneca Ab Benzamide derivatives and their use as cytokine inhibitors
CN1158266C (zh) 1998-10-01 2004-07-21 阿斯特拉曾尼卡有限公司 化合物
US6194399B1 (en) 1998-10-09 2001-02-27 Scriptgen Pharmaceuticals, Inc. Aryldiamine derivatives useful as antibacterial agents
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
BR0009041A (pt) * 1999-03-17 2001-12-26 Astrazeneca Ab Derivado de amida, processo para a preparação deum derivado de amida, composição farmacêutica,uso de um derivado de amida, e, método paratratar doenças ou quadros clìnicos mediados porcitocinas
ES2219319T3 (es) 1999-03-17 2004-12-01 Astrazeneca Ab Derivados de amida.
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
CA2471114C (en) * 2001-12-21 2012-03-20 The Wellcome Trust Mutant b-raf polypeptide and a use thereof in the diagnosis of cancer
WO2003068746A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
WO2004064733A2 (en) * 2003-01-15 2004-08-05 Board Of Regents, University Of Texas System The use of c-raf inhibitors for the treatment of neurodegenerative diseases
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
US7691870B2 (en) 2003-07-11 2010-04-06 Merck Patent Gmbh Benzimidazole carboxamides as raf kinase inhibitors
JP4777887B2 (ja) 2003-07-23 2011-09-21 バイエル、ファーマシューテイカルズ、コーポレイション 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US20060025485A1 (en) * 2004-07-01 2006-02-02 Kyle Holen Hydroxybenazamide compounds for treatment of cancer
MX2007002433A (es) * 2004-09-01 2007-05-04 Astrazeneca Ab Derivados de quinazolinona y su uso como inhibidores de b-raf.
TW200635899A (en) * 2004-12-22 2006-10-16 Astrazeneca Ab Chemical compounds
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
WO2007059157A1 (en) * 2005-11-14 2007-05-24 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
EA200970700A1 (ru) 2007-04-20 2010-02-26 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний
CN102933560A (zh) * 2010-05-11 2013-02-13 科瑞塞尼生物科技有限公司 4,6-二苯甲酰氨基-2-甲基-嘧啶衍生物及其用于治疗癌症的用途
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
KR20140057360A (ko) 2011-08-29 2014-05-12 티코나 엘엘씨 고유동성 액정 중합체 조성물
US8906258B2 (en) 2011-08-29 2014-12-09 Ticona Llc Heat-resistant liquid crystalline polymer composition having a low melting temperature
WO2013032971A1 (en) 2011-08-29 2013-03-07 Ticona Llc Melt-extruded substrate for use in thermoformed articles
WO2013032975A1 (en) 2011-08-29 2013-03-07 Ticona Llc Thermotropic liquid crystalline polymer with improved low shear viscosity
KR20140057629A (ko) 2011-08-29 2014-05-13 티코나 엘엘씨 방향족 아마이드 화합물
TW201319118A (zh) 2011-08-29 2013-05-16 Ticona Llc 低熔融黏度液晶聚合物之熔融聚合
US9045685B2 (en) 2011-08-29 2015-06-02 Ticona Llc Cast molded parts formed from a liquid crystalline polymer
KR20140059825A (ko) 2011-08-29 2014-05-16 티코나 엘엘씨 고유동성 액정 중합체 조성물
PL2830662T3 (pl) 2012-03-29 2019-02-28 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2014130275A2 (en) 2013-02-22 2014-08-28 Ticona Llc High performance polymer composition with improved flow properties
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4327827A3 (en) 2019-12-30 2024-05-29 Deciphera Pharmaceuticals, LLC Amorphous kinase inhibitor formulations and methods of use thereof
JP2023509628A (ja) 2019-12-30 2023-03-09 デシフェラ・ファーマシューティカルズ，エルエルシー １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2552492A (en) * 1991-08-23 1993-03-16 United States of America as represented by The Secretary Department of Health and Human Services, The Raf protein kinase therapeutics

Also Published As

Publication number Publication date
NO992336D0 (no) 1999-05-14
CA2267782A1 (en) 1998-05-28
GB9623833D0 (en) 1997-01-08
WO1998022103A1 (en) 1998-05-28
ZA9710314B (en) 1998-05-18
AU4956297A (en) 1998-06-10
JP2001504478A (ja) 2001-04-03
EP0941084A1 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
NO992336L (no) Raf-kinase-inhibitorer
DE69918404D1 (de) Aminophenoxyessigsäure derivate als neuroschützende mittel
EA200400944A1 (ru) Замещенные производные тетрациклина, фармацевтическая композиция и способ лечения субъекта с их использованием
DE69921804D1 (de) Benzamid-derivate zur behandlung cytokin-vermittelter krankheiten
HUP0104060A2 (hu) Benzamid-származékok és felhasználásuk citokin-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BG93979A (bg) Производни на n-(4-пиперидинил)(дихидробензофуран или дихидро-2н-бензопиран)карбоксамид, фармацевтичен състав, който ги съдържа, метод за получаване на производните и приложението им
RU95108387A (ru) Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина
EE03435B1 (et) Maatriksmetalloproteaasi inhibeeriva aktiivsusega ühendid, nende valmistamismeetodid ja kasutamine, vaheprodukt ja kompositsioon
RU95108243A (ru) Производные амидов вальпроновой и 2-вальпроеновой кислоты, фармацевтическая композиция, способы лечения
EE03139B1 (et) Piperasiiniderivaadid, nende kasutamine ja farmatseutiline kompositsioon
HUP0002272A2 (hu) Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
HUP0100558A2 (hu) S-Oxid- és S,S-dioxid-tetrahidrotiopirán-fenil-oxazolidinon-származékok, e vegyületek alkalmazása gyógyászati készítmények előállítására, valamint eljárás e vegyületek gátló hatásának meghatározására humán-monoamin-oxidázzal szemben
RU95105435A (ru) N-замещенные производные 3-азабицикло [3.2.0]гептана в качестве нейролептического средства
WO2003082861A3 (en) Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
ATE270550T1 (de) Wirkstoff zum schutz für organ oder gewebe
ATE153666T1 (de) Phosphono-arylethanolamin-verbindungen mit antihyperglykämischer und/oder antiobeser wirkung
ES8606337A1 (es) Un procedimiento para preparar nuevas benzamidas con actividada antagonista de 5-ht.
UA49005C2 (uk) Похідні камптотецину (варіанти), спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
HU895336D0 (en) Process for producing beta-delta-phenylthioxylosides and pharmaceutical compositions comprising such compounds as active ingredient
BG88028A (bg) Амиди на циклометилен-1,2-дикарбоксилни киселини с терапевтична активност,методи за получаването им и фармацевтични състави, които ги съдържат
DE69330601D1 (de) Serotoninergische ergolin derivate
ES8300095A1 (es) "un procedimiento para preparar derivados de halofenil-piridil-alilamina".
RU95104890A (ru) Новые стероиды, содержащие в положении 20 аминозамещенную цепь, метод и промежуточные продукты подготовки данного метода, их применение в качестве медикаментов и включающие их фармацевтические соединения
DE69402004D1 (de) Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application